Harrow Health (HROW) Given Consensus Recommendation of “Strong Buy” by Brokerages

Shares of Harrow Health (NASDAQ:HROW) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.

Brokerages have set a twelve-month consensus target price of $10.75 for the company and are forecasting that the company will post $0.12 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Harrow Health an industry rank of 101 out of 255 based on the ratings given to its competitors.

A number of brokerages have recently weighed in on HROW. ValuEngine downgraded Harrow Health from a “hold” rating to a “sell” rating in a report on Wednesday. Zacks Investment Research upgraded Harrow Health from a “sell” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Friday, March 15th.

In other news, Director Robert J. Kammer sold 10,000 shares of Harrow Health stock in a transaction on Friday, February 1st. The stock was sold at an average price of $5.86, for a total transaction of $58,600.00. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 13.78% of the company’s stock.

Shares of HROW stock traded up $0.19 on Friday, reaching $4.98. 245,900 shares of the company’s stock traded hands, compared to its average volume of 277,100. Harrow Health has a 12-month low of $1.71 and a 12-month high of $7.20. The company has a current ratio of 2.76, a quick ratio of 2.61 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $122.46 million, a price-to-earnings ratio of 8.20 and a beta of 0.07.

Harrow Health (NASDAQ:HROW) last issued its quarterly earnings results on Tuesday, March 12th. The company reported $0.77 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.07). Harrow Health had a net margin of 35.35% and a return on equity of 177.27%. The business had revenue of $11.38 million for the quarter, compared to analysts’ expectations of $10.92 million. On average, sell-side analysts predict that Harrow Health will post -0.02 EPS for the current year.

About Harrow Health

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

See Also: How to read a candlestick chart

Get a free copy of the Zacks research report on Harrow Health (HROW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.